EUCTR2019-002217-19-IT进行中（未招募）1 期
Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) - na
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject must be = 18 years old, have newly diagnosed AML with intermediate or adverse risk cytogenetics, have confirmed CR or CRi following completion of planned induction and consolidation chemotherapy, have achieved first CR + CRi within 4 months of enrollment or no more than 75 days since last dose of conventional chemotherapy, and have an Eastern Cooperative Oncology Group (ECOG) performance status of = 2.
- •The key laboratory requirements are as follows:
- •creatinine clearance = 30 mL/minute; calculated by the Cockcroft Gault formula or measured by 24-hour urine collection;
- •bilirubin < 3.0 × upper limit of normal (ULN) (adequate liver function);
- •absolute neutrophil count = 1,500/µL;
- •platelets = 100,000/mm3.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •History of APL.
- •History of active central nervous system involvement with AML.
研究者
相似试验
进行中（未招募）
1 期
Randomized, Open-label, 2-Arm, Multicenter, Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyEUCTR2019-002217-19-FRAbbVie Deutschland GmbH & Co. KG360
进行中（未招募）
2 期
Clinical trial to Evaluate Treatment Compliance, Efficacy and Safety of an Improved new formulation of Deferasirox in the form of Granules in children of the age 2 to 18 Years Old who have Iron overload.CTRI/2017/10/010252ovartis Healthcare Private Limited6
进行中（未招募）
1 期
Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy or are intolerant or unable to take interferoChronic hepatitis CMedDRA version: 18.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-003751-38-FRovartis Pharma Services AG52
进行中（未招募）
不适用
Phase II/III, Multicenter, Open-label, Randomized Study Comparing Autologous Intravesical Macrophage Cell Therapy (Bexidem”) to Intravesical BCG-Therapy in Patients With Superficial Papillary Bladder Cancer Who Have Undergone Complete Transurethral ResectioBLADDER CANCER AFTER TRANSURETRHAL RESECTIOEUCTR2004-003699-13-ESINMUNO DESIGNED MOLECULES (IDM)650
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab/docetaxel in patients with breast cancer that spread to other tissues.First-line treatment of patients with HER2 negative metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2006-001365-42-ATF. Hoffmann-La Roche Ltd424